Phaseline

Companies › J Ints Bio

J Ints Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JIN-A02
4th generation EGFR tyrosine kinase inhibitor
EGFRPhase 1EGFR Mutant Advanced Non-small Cell Lung Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05394831JIN-A02Phase 1EGFR Mutant Advanced Non-small Cell Lung CancerOncologySep 2026

Targets

EGFR (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.